Clinuvel Pharmaceuticals (ASX: CUV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clinuvel Pharmaceuticals Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clinuvel Pharmaceuticals (ASX: CUV)
Latest News
Share Gainers
These ASX shares have more than doubled in value in 12 months
Share Gainers
Why CLINUVEL, Costa, Nearmap, and Treasury Wine Estates shares jumped higher today
Share Gainers
Why CLINUVEL, Integrated Research, Nearmap, and Noni B shares are storming higher today
Share Gainers
Why the CLINUVEL Pharmaceuticals share price surged 13% higher today
Share Gainers
Why these 4 ASX shares are storming higher today
Share Gainers
Why the Clinuvel Pharmaceuticals share price is up 111% in 2018
Growth Shares
3 small cap healthcare shares to buy today
Healthcare Shares
The CSL Limited (ASX:CSL) share price is down 24% from its peak – is it time to buy?
Share Fallers
Why these 4 ASX shares are tumbling lower today
Share Fallers
Clinuvel Pharmaceuticals Limited (ASX:CUV) shares have been smashed today
Share Gainers
These ASX shares have more than doubled in value in 12 months
52-Week Highs
Is it too late to buy these market-beaters?
Frequently Asked Questions
-
Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.
-
Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.
-
Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.
-
Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.
CUV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.
Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.
